1200 PsA pts 6 countries IL17is as effective as TNFi and JAK despite more failed bDMARDs and monotherapy & faster onset action than IL23s ⁦@RheumNow⁩ #EULAR2024 https://t.co/SM5CA7KUvd

#EULAR2024 LBA0009 Phase 3 Open label H2H RCT of Ixekizumab vs in jPsA & enthesitis-related arthritis showed similar ACR30 response rates at Wk16 (IXE=89%; ADA=95%). Open label and long-term follow up for IXE is ongoing to assess for sustainment @RheumNow https://t.co/lk42I7Mn8B

New reccs for knee/hip #OA w/2 overarching principles 1. Biopsychosocial approach 2.Individualized Rx w/shared decision making (includes education, diet/exercise, healthy weight, appropriate assistive device/footware, modify work factors, pain coping skills) #EULAR24 @rheumnow https://t.co/0LVLBMGO7L

Different pathways of auto inflammatory disease which is an amplifier system. Always check the phenotype first before genotype. Kasner D #EULAR2024 @RheumNow https://t.co/MtPzsVBNjn

#EULAR2024 LBA0010 Promising Tx with diff mode of action in antibody+ #Sjogren. Phase 2 RCT Nipocalimab, anti-neonatal Fc receptor (FcRn)Ab that reduces IgG, met primary endpoint (clinESSDAI). Low SIE but doubled in lowest dose vs PBO (unrelated to IgG). On to Phase3 @RheumNow https://t.co/NlCc2l4zFL

#EULAR2024 LBA0007 More evidence on deep Bcell depletion in #lupus. Open label trial of Daratumumab, anti-CD38 plasma cell Ab showed rapid reduction in biomarker endpoint, dsDNA, as well as SRI-4 & CLASI-A at Wk12. No SAE but longer F/U needed since IgG reduced by 6g/L @RheumNow https://t.co/IIFPYV9oIr

Thanks for these updates recommendations for hip/knee OA -- but, still not much has changed. #eular2034 https://t.co/NMwFWxwocF

The Role of Psychosocial Determinants in the Management of RA Dr. Mrinalini Dey reports from Eular 2024 in Vienna, Austria about an abstract she will present during the meeting, POS0309. https://t.co/o3vqHJnQHz https://t.co/ibMrNNCmUr

Do we need more IL-17 and JAK Inhibitors in Spondyloarthritis? Dr. Eric Ruderman shares his perspectives on the following abstracts being presented at #EULAR2024 in Vienna, Austria: OP0195 LBA0005 POS0803 OP0138 https://t.co/MnefRxYqMh https://t.co/Mwq4s7eTKY

AI meets Rheumatology: ChatGPT and patient response optimization Large language models like ChatGPT, trained on vast text data, are revolutionizing healthcare by understanding and generating human-like language. https://t.co/GzT9UvndTX https://t.co/ziOh8oCbZ9

A beautiful free concert in Vienna #EULAR2024 ⁦@eular_org⁩ ⁦@RheumNow⁩ https://t.co/8YPWbkmTUr